The strong preclinical data for PRT13722 significantly de-risks the program and enhances its potential as a best-in-class therapy for HR+/HER2- breast cancer. Traders should monitor upcoming clinical trial initiation in 2H 2026 as the next major catalyst. The improved safety profile could enable combination therapies, potentially expanding the addressable market. The $106M cash runway provides sufficient funding through anticipated clinical milestones.
Price Chart
Executive Summary
Prelude Therapeutics presented positive preclinical data for its lead drug candidate PRT13722, a first-in-class, highly selective oral KAT6A degrader for treating HR+/HER2- breast cancer. The data shows complete tumor regressions as monotherapy in multiple models, improved efficacy over existing treatments, and a better safety profile with reduced bone marrow toxicity. The company remains on track for an IND filing in mid-2026 and Phase 1 clinical trial initiation in the second half of 2026.
Key Facts
- Presented preclinical data for PRT13722 at AACR Annual Meeting 2026
- PRT13722 is a first-in-class, highly selective oral KAT6A degrader for HR+/HER2- breast cancer
- Data shows complete tumor regressions as monotherapy in multiple CDX and PDX models
- Demonstrates improved efficacy over prifetrastat + fulvestrant combination
- Shows improved preclinical hematological safety profile compared to prifetrastat
- On track for IND filing in mid-2026 and Phase 1 clinical trial initiation in 2H 2026
- Cash runway expected into Q2 2027 with $106 million in cash and equivalents as of Dec 31, 2025
Financial Impact
No immediate financial impact as this is preclinical data, but positions the company for future value creation through clinical development
Risk Factors
- Preclinical results may not translate to human clinical efficacy
- Competitive landscape in HR+/HER2- breast cancer is evolving with other KAT6 inhibitors in development
- Regulatory hurdles in advancing from preclinical to clinical stage
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-162620 |
| Document: d135229d8k.htm | 0001193125-26-162620 |
| Document: d135229dex991.htm | 0001193125-26-162620 |
| Document: 0001193125-26-162620-index-headers.html | 0001193125-26-162620 |
| Document: 0001193125-26-162620-index.html | 0001193125-26-162620 |
| Document: 0001193125-26-162620.txt | 0001193125-26-162620 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 5w ago | Institutional Cluster | $4.85 $4.31 | ▼ −11.13% | ▼ −10.41% | $3.88 (−20.00%) |
Sep 10, 2026 6w ago | 8-K | $4.67 $4.59 | ▼ −1.71% | ▼ −2.57% | $3.88 (−16.92%) |
Sep 10, 2026 6w ago | Press Release | $4.67 $4.59 | ▼ −1.71% | ▼ −2.57% | $3.88 (−16.92%) |
Aug 11, 2026 11w ago | 8-K | $5.32 $5.73 | ▲ +7.71% | ▲ +7.46% | $3.88 (−27.07%) |
Aug 11, 2026 11w ago | Press Release | $5.32 $5.73 | ▲ +7.71% | ▲ +7.46% | $3.88 (−27.07%) |
May 12, 2026 24w ago | 8-K | $4.64 $4.66 | ▲ +0.43% | ▼ −0.14% | $3.88 (−16.38%) |
May 12, 2026 24w ago | Press Release | $4.64 $4.66 | ▲ +0.43% | ▼ −0.14% | $3.88 (−16.38%) |
Apr 28, 2026 26w ago | 3 | $4.27 $4.27 | · 0.00% | ▼ −1.02% | $3.88 (−9.13%) |
Apr 21, 2026 27w ago | Insider Cluster | $4.27 $5.23 | ▲ +22.48% | ▲ +21.46% | $3.88 (−9.13%) |
Apr 20, 2026 27w ago | 8-K | $4.51 $4.62 | ▲ +2.44% | ▲ +3.09% | $3.88 (−13.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers